Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal – Nasdaq
San Francisco Chronicle |
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
Nasdaq Biotech giant Gilead Sciences, Inc. 's GILD $11.8 billion deal to buy CAR–T cancer therapy designer, Kite Pharma, Inc. KITE has made two other leading independent CAR–T developers, Juno Therapeutics, Inc. JUNO and Bluebird Bio, Inc. BLUE hot takeover … Gilead to Fly High with Kite Pharma Acquisition for $11.9B 'Game-changer' cancer treatment is focus of Gilead's $12 billion cell therapy deal Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma Closes |
